MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) recently disclosed updates to the employment agreements of key executive officers in a Form 8-K filing dated February 1, 2025. The company entered into ...
In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...
Berry Global Group, Inc. BERY reported first-quarter fiscal 2025 (ended December 2024) adjusted earnings of $1.09 per share, ...
CoreLogic®, a leading global property information, analytics and data-enabled solutions provider, today released the ...